Kim R Saverno1, Brian Seal2, Michael J Goodman3, Kellie Meyer4. 1. Graduate student in Pharmaceutical Economics, Policy, and Outcomes, University of Arizona College of Pharmacy, Tucson. 2. Senior Director, sanofi-aventis, Bridgewater, NJ. 3. Assistant Professor, University of Utah College of Pharmacy, Salt Lake City. 4. Associate Director, Xcenda, Palm Harbor, FL.
Abstract
BACKGROUND: Allergic rhinitis causes significant economic losses and substantial reductions in quality of life. Improving a patient's symptoms can therefore enhance the patient's quality of life. OBJECTIVE: To measure the relative cost-effectiveness of prescription second-generation antihistamines (levocetirizine, desloratadine, and fexofenadine) and montelukast based on their impact on quality of life in patients with uncomplicated allergic rhinitis. METHODS: A retrospective, cost-effectiveness model was constructed using 1-year costs to managed care payers and using the Rhinoconjunctivitis Quality of Life Questionnaire to measure the quality of life in patients taking prescription second-generation antihistamines or montelukast for the treatment of allergic rhinitis. Clinical trial results for levocetirizine, desloratadine, fexofenadine (brand and generic), or montelukast were combined as standardized mean differences to create a pooled effectiveness measure. The costs of prescription drugs and physician office visits for allergic rhinitis were used as direct costs measures. Sensitivity was assessed by a Monte Carlo simulation run 1000 times. RESULTS: All the drugs in the study showed significant improvement in quality of life, with levocetirizine showing the greatest improvement. The incremental cost-effectiveness of levocetirizine dominated montelukast (incremental cost-effective ratio, -1317; 95% confidence interval, -7471, -212). The incremental cost-effectiveness favored levocetirizine compared with desloratadine and branded fexofenadine. CONCLUSION: There are significant differences in the cost-effectiveness of various oral prescription agents with regard to improving quality of life of patients with allergic rhinitis.
BACKGROUND:Allergic rhinitis causes significant economic losses and substantial reductions in quality of life. Improving a patient's symptoms can therefore enhance the patient's quality of life. OBJECTIVE: To measure the relative cost-effectiveness of prescription second-generation antihistamines (levocetirizine, desloratadine, and fexofenadine) and montelukast based on their impact on quality of life in patients with uncomplicated allergic rhinitis. METHODS: A retrospective, cost-effectiveness model was constructed using 1-year costs to managed care payers and using the Rhinoconjunctivitis Quality of Life Questionnaire to measure the quality of life in patients taking prescription second-generation antihistamines or montelukast for the treatment of allergic rhinitis. Clinical trial results for levocetirizine, desloratadine, fexofenadine (brand and generic), or montelukast were combined as standardized mean differences to create a pooled effectiveness measure. The costs of prescription drugs and physician office visits for allergic rhinitis were used as direct costs measures. Sensitivity was assessed by a Monte Carlo simulation run 1000 times. RESULTS: All the drugs in the study showed significant improvement in quality of life, with levocetirizine showing the greatest improvement. The incremental cost-effectiveness of levocetirizine dominated montelukast (incremental cost-effective ratio, -1317; 95% confidence interval, -7471, -212). The incremental cost-effectiveness favored levocetirizine compared with desloratadine and branded fexofenadine. CONCLUSION: There are significant differences in the cost-effectiveness of various oral prescription agents with regard to improving quality of life of patients with allergic rhinitis.
Authors: Ron Z Goetzel; Stacey R Long; Ronald J Ozminkowski; Kevin Hawkins; Shaohung Wang; Wendy Lynch Journal: J Occup Environ Med Date: 2004-04 Impact factor: 2.162
Authors: Charles E Lamb; Paul H Ratner; Clarion E Johnson; Ambarish J Ambegaonkar; Ashish V Joshi; David Day; Najah Sampson; Benjamin Eng Journal: Curr Med Res Opin Date: 2006-06 Impact factor: 2.580
Authors: William F Schoenwetter; Leon Dupclay; Sireesh Appajosyula; Marc F Botteman; Chris L Pashos Journal: Curr Med Res Opin Date: 2004-03 Impact factor: 2.580